Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorTanta University
About this trial
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Eligibility criteria
Qualifiers
Age from 18 to 65 years old.
Gender: female.
Positive breast cancer women who are scheduled to receive Doxorubicin.
Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
Disqualifiers
Pregnant or breastfeeding women.
Women with HER-2 positive of breast cancer.
Formerly treated with Doxorubicin.
Patients with a known hypersensitivity to any of the used drugs.
Trial design
Treatments tested in this trial
- Group 1 (Doxorubicin group)
- Group 2: Vitamin D group
- Group 3: melatonin group
Treatment groups
90 Participants
are divided into 3 treatment groupsLocations
1Tanta University Tanta Egypt
Sponsors and collaborators
Tanta University
Lead sponsor
Source ClinicalTrials.gov